SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc.
(Nasdaq: SGXP) announced today details of two presentations from the
Company's BCR-ABL program for the treatment of chronic myelogenous leukemia
(CML) at the upcoming American Society of Hematology's 49th Annual Meeting
and Exposition. The conference is being held December 8th - 11th, 2007 in
The schedule for these sessions, together with the abstract information, is listed below:
Date: Saturday, December 8, 2007 from 5:30pm - 7:30pm EST
Session Type: Poster Session, Board #172-I
Title: "Co-Crystal Structures of 7-Azaindole Inhibitors of
Wild-Type and T315I Imatinib-Resistant Mutant Forms of the
BCR-ABL Tyrosine Kinase."
Description: This poster presentation describes how the SGX393 chemical
family of BCR-ABL inhibitors discovered by SGX can provide
potent, selective inhibition of both wild type and major
drug resistant mutant forms of BCR-ABL including T315I.
The poster discusses the impact of seven BCR-ABL mutations
on the co-crystal structures of the SGX393 family of
inhibitors, including the challenging T315I, G250E and
F317L mutations. SGX393 represents an illustrative example
of how the integrated SGX FAST fragment-based,
structure-guided drug discovery platform can be used to
generate high-quality, low molecular weight inhibitors of
|SOURCE SGX Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved